Insmed initiates trial for TPIP in pulmonary hypertension associated with interstitial lung disease
Insmed Incorporated has initiated a 24-week clinical trial to evaluate the efficacy of Treprostinil Palmitil Inhalation Powder (TPIP) in improving exercise capacity in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD).